RE:Number needed to treat for RVX-208, the NNT ?Thanks for sharing that link esopbykelso. However, I found it to be incomplete and mostly irrelevant to recent CVOTs as well as the patient population in BETonMACE. Unless I missed it, I see nothing on NNT for the SGLT2 inhibitors or GLP-1R agonists, which have been found to elicit reductions in 3-point MACE in recent CVOTs involving type 2 diabetes patients. Not surprisingly, it also does not include the NNT for the recent Amarin Vascepa REDUCE-IT CVOT.
The statins for ACS category only looked at studies that initiated statin therapy within 14 days following the onset of ACS, and only followed up for 4 months. There was no stratification based upon baseline LDL-C levels. In general, the more one lowers LDL-C and the longer one maintains that lowered LDL-C, the greater the observed reduction in MACE. So whether is it statins, PCSK9 inhibitors, ezetimibe, bempedoic acid, or a combination of two or more of these, the lower the LDL-C goes and the longer one follows the patients, the more cardiovascular benefit one will observe. On that note, that NNT link doesn't include any NNT data for these other LDL-C lowering drug CVOT trials. Furthermore, the FOURIER and ODYSSEY PCKS9 CVOTs showed that patients with baseline LDL-C above 100 mg/dl experienced the greatest MACE reduction. Overall, that study in the NNT link you shared seems a gross oversimplification of the statin/LDL-C MACE reducing effect.
BDAZ